1
), that revealed enhanced expression in response to exogeneously expressed AXIN1 but not to LacZ, a control gene. The AXUD1 gene consists of ®ve exons and encodes a transcript with an open reading frame of 1767 bp. A 3.2-kb transcript of AXUD1 was expressed in all human tissues examined, most abundantly in lung, placenta, skeletal muscle, pancreas and leukocyte. By radiationhybrid mapping we assigned its chromosomal location at 3p22, a region where frequent loss of heterozygosity has been reported in lung, renal, prostate, breast and cervical cancers. AXUD1 was frequently down-regulated in lung, kidney, liver and colon cancers compared with their corresponding normal tissues, suggesting that AXUD1 may have a tumor-suppressor function in those organs. Oncogene (2001) 20, 5062 ± 5066.
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The Wnt signaling pathway plays important roles in axis formation in early vertebrate development (McMahon and Moon, 1989) . Axin, a negative regulator of this pathway, promotes phosphorylation of serine/threonine in exon 3 of b-catenin by forming a complex with APC and GSK-3b Kishida et al., 1998; Yamamoto et al., 1999) .
Phosphorylated b-catenin is quickly degraded via an ubiquitin-proteosome pathway in the cytoplasm (Behrens et al., 1998; Nakamura, 1997) . Upon Wnt signaling, phosphorylation of b-catenin is suppressed through unde®ned mechanisms, when b-catenin functions as a transcriptional regulator in the nucleus coupled with molecules of the Tcf/LEF family (He et al., 1998; Morin et al., 1997) . Until now a number of downstream genes such as c-Myc (He et al., 1998) , cyclinD1 (Shtutman et al., 1999; Tetsu and McCormick, 1999) , c-jun, fra-1, uPAR, ZO-1 (Mann et al., 1999) , MMP7 (Brabletz et al., 1999) , NBL4 , DRCTNNB1A , and MCP-3 have been reported. However, the precise regulatory mechanisms remain to be resolved.
Impaired regulation of the Wnt signaling pathway is often involved in tumors that arise in human colon, liver, prostate, uterus, stomach, skin and brain (Chan et al., 1999; Fukuchi et al., 1998; Iwao et al., 1998; Miyoshi et al., 1998; Smits et al., 2000; Voeller et al., 1998; Zurawel et al., 1998) . Deregulation of this pathway can result from genetic changes in the APC, CTNNB1, AXIN1 or AXIN2 genes (da Costa et al., 1999; Korinek et al., 1997; Miyoshi et al., 1998; Morin et al., 1997; Satoh et al., 2000) . We previously reported that inactivation of Axin by genetic alterations was a frequent feature of hepatocellular carcinomas . Moreover, adenovirus-mediated gene transfer of wild-type AXIN1 suppressed growth and induced apoptosis not only in Axin-de®cient cells but also in cells with mutant b-catenin or in APC-de®cient cells .
To identify additional genes regulated by the bcatenin/Tcf4 complex and to clarify the detailed mechanism of apoptosis induced by AXIN1, we investigated genes whose expression was altered in response to the transduction of AXIN1 into LoVo cells using in-house cDNA microarray slides representing 9216 independent genes. Preparation, hybridization and detection of microarray slides as well as data analysis were performed as described previously (Ono et al., 2000) . When we compared expression pro®les between LoVo cells infected with either adenoviruses expressing wild-type AXIN1 (Ad-Axin) or LacZ (AdLacZ), a gene with in-house accession number A5900 showed approximately 2.5-fold up-regulation by AXIN1 in the cancer cells. Subsequent semi-quantitative RT ± PCR experiments con®rmed increased expression of the A5900 gene by Ad-Axin, but not by Ad-APC expressing the 20-amino-acid repeat domain of wild-type APC (Figure 1 ). Similar induction was observed in other colon-cancer cell lines (SNUC2A and SW480; data not shown).
By screening in a human spleen cDNA library (Stratagene) using the A5900 PCR product as a probe and subsequent 5' rapid ampli®cation of cDNA ends (5'RACE) using a Marathon cDNA ampli®cation kit (Clontech), we identi®ed a putative full-length cDNA sequence corresponding to A5900 and termed it AXUD1 (Axin1 up-regulated 1 ). Its cDNA sequence consisted of 3182 nucleotides with an open reading frame of 1767 bp, encoding a deduced 589-amino-acid protein (DNA sequence is available from GenBank, accession number AB053121). A homology search with the nucleotide sequence and predicted amino-acid sequence using BLAST program by accessing databases in NCBI (National Center for Biotechnology Information, http://www.ncbi.nlm.nih.gov/) revealed high identity of AXUD1 to a 5' truncated cDNA sequence (GenBank accession number of AL117565), a genomic sequence (NT005498) and a number of ESTs. Using domain-search programs PROSITE and SMART, we looked for conserved protein motifs in the putative AXUD1 product, but failed to identify any matches with archived motifs.
To examine the expression of AXUD1 in human tissues, we performed Northern-blot analysis using the AXUD1 cDNA clone as a probe. A 3.2-kb transcript was expressed in all human tissues examined, with expression being most abundant in lung, placenta, skeletal muscle, pancreas and leukocyte (Figure 2 ).
In addition, we performed radiation-hybrid mapping analysis using the GeneBridge 4 (GB4) and G3 radiation hybrid mapping panels (Research Genetics) according to the supplier's protocol (Miano et al., 1997) and de®ned its position to approximately 3.46cR from D3S 1561, located at chromosomal band 3p22. In line with our data, an EST clone (Hs.6607) that corresponded to AXUD1 was mapped between D3S1609 and D3S1260 according to Gene Map 98 from NCBI (http://www.ncbi.nlm.nih.gov/genemap/). By comparing genomic with cDNA sequences, we determined that AXUD1 consists of ®ve exons and covers a 12 kb genomic region.
To investigate the sub-cellular localization of AXUD1 protein in mammalian cells, we transiently transfected a plasmid expressing¯ag-tagged AXUD1 protein (pFlag/AXUD1) into COS7 cells and observed the tagged protein by immunocytochemical staining. To con®rm expression of the tagged protein, a wholecell extract from transfected cells was separated by SDS ± PAGE, and tagged protein of M r 65000 was detected by Western blot analysis with an anti-Flag antibody (Figure 3a) . The protein was observed mainly in the nuclei of transfected cells (Figure 3b) .
By means of cDNA microarray analysis we identi®ed and characterized a novel human gene, AXUD1, whose expression was elevated in colon-cancer cells in response to transduction of wild-type AXIN1. However, its expression was not induced by the 20-aminoacid repeat domain of wild-type APC. Since infection with either Ad-Axin or Ad-APC was able to suppress transcriptional activity of the Tcf/LEF complex in LoVo cells (data not shown), the dierent eect of the two genes on AXUD1 expression implies that transcription of AXUD1 is independent of the Tcf/LEF complex.
Recent progress in basic research has revealed that several molecules in the Wnt signaling pathway play pleiotrophic roles; for example, b-catenin mediates Wnt signals and also regulates cell-to-cell adhesion associated with E-cadherin (Nakamura, 1997; Nusse and Varmus, 1992; van den Heuvel et al., 1989) , while APC functions as a negative regulator of Wnt signals and is also involved in nuclear export and cell motility (Rosin-Arbesfeld et al., 2000) . In line with this notion, APC induces CDX2, a gene involved in caudal determination, independent from the Tcf/LEF mediated transcription (da Costa et al., 1999) . Similarly, Axin may exert a variety of physiological functions, including suppression of b-catenin and upregulation of AXUD1 via a b-catenin/Tcf-independent pathway. Figure 1 Elevated expression of AXUD1 in LoVo cells in response to Ad-Axin. Human colon-cancer LoVo cells were cultured in HAM's F-12, supplemented with 10% fetal bovine serum and 1% antibiotic/antimycotic solution (Sigma Chemical Co) at 378C in humid air with 5% CO 2 . Construction and infection of adenoviruses expressing wild-type AXIN1, LacZ, or the 20-amino-acid repeat region of APC was carried out as described previously . The transfected cells were maintained at 378C for 72 h and total RNA was extracted. Semi-quantitative RT ± PCR was performed with the extracted RNAs as templates. Expression of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene served as an internal control. The primers for ampli®cation were GAPDHF (5'-ACAACAGCCTCAAGATCATCAG-3') and GAPDHR (5'-GGTCCACCACTGA CACGTTG-3') for GAPDH, and AX-UD1F (5'-GAGACAGGGCTGAAATCAGG-3'), AXUD1R (5'-GAAGTGCAGTGCCCAGAAAG-3') for AXUD1. Each PCR reaction was carried out in a 25 ml volume of 16PCR buer (TAKARA) for 5 min at 948C for initial denaturing, followed by 20 (for GAPDH) or 27 (for AXUD1) cycles of 948C for 30 s, 588C for 30 s and 728C for 30 s, in the GeneAmp PCR system 9700 (Perkin-Elmer)
The chromosomal location of AXUD1 at 3p22, where frequent LOH has been reported in human cancers arising from the lung (Wistuba et al., 1999) , kidney (Yokota et al., 1989) , prostate (Dahiya et al., 1997), breast (Deng et al., 1996) and uterine cervix (Wistuba et al., 1997) , led us to speculate that inactivation of AXUD1 may be involved in carcinogenesis of those organs. Therefore we compared expression Figure 2 Northern blot of AXUD1 in various human tissues. Molecular size is indicated at right. Human multiple-tissue blots (Clontech) were hybridized with the AXUD1 PCR product labeled by random-oligonucleotide-priming, using a Megaprime DNA labeling kit (Amersham Pharmacia Biotech). Pre-hybridization, hybridization and washing were performed according to the supplier's recommendations. The blots were autoradiographed with intensifying screens at 7808C for 24 h Figure 3 (a) Expression of¯ag-tagged AXUD1 protein in COS7 cells. To achieve a¯ag-tagged AXUD1 protein, we cloned the entire coding region of AXUD1 into pFlag-CMV vector (Kodak) and transfected the pFlag/AXUD1 into COS7 cells. The expression of¯ag-tagged AXUD1 protein in transfected cells was detected by Western blotting, in a manner described elsewhere . (b) Immunocytochemical staining of¯ag-tagged AXUD1 protein. Cells were stained with an anti-Flag antibody and visualized by anti-mouse secondary antibody conjugated with rhodamine as described previously AXUD1 is up-regulated by AXIN1 H Ishiguro et al of AXUD1 in cancer tissues from human lung, kidney, liver, and colon and their corresponding non-cancerous tissues, using semi-quantitative RT ± PCR. Expression was reduced in 14 of 19 colon cancers, 13 of 15 lung cancers, three of six renal cancers and eight of 10 HCCs examined (Figure 4 ). The increased expression was observed in none of the cases examined. Although we screened 50 lung cancers for mutations of AXUD1, we detected no genetic alterations (data not shown). However, in addition to allelic losses, transcriptional silencing due to methylation in the promoter region could be responsible for downregulation of AXUD1. This possibility remains to be examined.
We reported earlier that transfection of Ad-Axin induced apoptosis in various human liver-and coloncancer cells . It is noteworthy that this eect was observed not only in SNU423 or Alexander cells, which express mutant AXIN1, but also in Huh7 or HepG2 cells, which contain wild-type AXIN1 . Therefore overexpression of Axin may induce cell death independently of Tcf/ LEF mediated transcription. Although further investigations are needed to clarify the physiological role of AXUD1 protein in cells, it may play a crucial role in the apoptotic process induced by Axin.
Since AXIN1 is a good candidate for a gene-therapy approach to treatment of human cancers, identi®cation and characterization of genes regulated by Axin will provide a better understanding of the carcinogenetic process and may identify novel therapeutic targets. Investigation of the function of AXUD1, for example, may lead to better diagnosis and yield clues for developing novel anti-cancer drugs and preventive agents. 
